Granules is completing remediation efforts at its Gagillapur facility while investing in R&D for ADHD and oncology treatments, alongside peptide synthesis capabilities. The company faces operational challenges driven by integration costs from the Senn Chemicals acquisition and ongoing regulatory compliance expenses.
Cyborg Score Rationale
Q3 FY26 showed strong performance with net profit rising 27.7% to ₹150.2 crore and revenue growing 22% to ₹1,387.9 crore, with EBITDA margins improving to 22.2%. However, significant regulatory headwinds and ongoing compliance issues create near-term uncertainty despite positive operational momentum.
Top Insights
Granules Pharmaceuticals received tentative USFDA approval for Amphetamine Extended-Release tablets for ADHD treatment, a product with addressable market of $172 million and limited generic competition.
Granules Life Sciences completed FDA GMP inspection at Hyderabad facility in December 2025 with five procedural observations unrelated to data integrity or product safety.
Granules India received a Warning Letter from the US FDA regarding its Gagillapur facility, creating significant regulatory and market sentiment headwinds.
February 2026: Allotted 2.5 crore convertible warrants at Rs.585 and 51.28 lakh shares for Rs.300 crore capital infusion.
Named Competitors
APIs & Generic Formulations — Integrated pharmaceutical with broader API and dosage portfolio
APIs & Generic Formulations — Large-scale API and generic manufacturer
APIs & Generic Formulations — Specialized API and intermediate manufacturer
APIs & Generic Formulations — Integrated pharma with significant API business
Recent Developments
(February 2026) Convertible warrants and preferential share allotment of Rs. 300 crore approved for capital strengthening
(January 2026) Q3 FY26 earnings beat estimates with 27.7% profit growth and 22% revenue growth; ADHD product tentative approvals
(December 2025) FDA GMP inspection completed at Hyderabad Life Sciences facility with only procedural observations
(Prior) FDA Warning Letter issued to Gagillapur facility due to compliance issues
Open the full interactive Granules India Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.